FDA Approves Lilly's Orforglipron; Trump Pharma Tariffs Loom
FDA approves Eli Lilly's oral obesity pill orforglipron (Foundayo) while Trump eyes 100% tariffs on imported pharmaceuticals and drug ingredients.
GLP-1 receptor agonists
3 articles tagged "GLP-1 receptor agonists"
Oral Obesity Pill Phase 2 Results & Cholesterol Guidelines 2026
Structure Therapeutics reports 16% weight loss in Phase 2 oral GLP-1 trial, plus GSK's Arexvy expansion and new cholesterol guideline updates.
Wegovy Linked to Higher Ischemic Optic Neuropathy Risk
New FAERS analysis finds Wegovy carries nearly fivefold higher ischemic optic neuropathy risk vs. Ozempic, raising ocular safety concerns for GLP-1 drugs.
By Sarah Tanaka